Medicare GLP-1 Bridge's $50 Copay Shuts Out Sicker Seniors

A popular discount with a narrow entrance

In July, Medicare began paying for obesity drugs for the first time. The program behind it is the Medicare GLP-1 Bridge, a temporary demonstration run by the Centers for Medicare & Medicaid Services (CMS). It lets eligible Part D enrollees get Wegovy, the Zepbound KwikPen or the oral drug Foundayo for a flat $50 a month, and it runs through December 31, 2027.317 People have signed up fast. White House figures reported by AARP put enrollment above 500,000 in the first two months, and CMS Administrator Mehmet Oz has said the number reached 600,000. Those figures have not been independently verified.23 Walgreens and CVS Health have each filled more than 100,000 prescriptions through the program, and Walgreens' chief pharmacy officer said volume was far ahead of what the company expected.26

The headline price leaves out a lot. Coverage of the program has pointed to three separate catches. The biggest one is easy to miss: the program turns away some of the sickest people who want these drugs. In practice, a person with obesity plus type 2 diabetes or sleep apnea can pay several times more than a person with obesity alone.

Why the diagnosis rule backfires

The $50 price only applies when the drug is prescribed for weight management. CMS bars anyone diagnosed with type 2 diabetes, moderate to severe obstructive sleep apnea, or noncirrhotic MASH with moderate to advanced liver scarring. It applies that bar even when the person otherwise meets every clinical requirement.12 The agency's reasoning is that Part D plans can already cover GLP-1s for those conditions, so the patients should get the drugs there.5 Anyone who has already had a GLP-1 paid for by their Part D plan is also shut out, though they can keep getting the drug through that plan.17

On paper, that looks like sensible cost control. For patients, the result can be backwards. NPR's reporting found that people sent back to their Part D plans can face copays of hundreds of dollars a month, and one clinician described patients who went through prior authorization and step therapy only to find GLP-1 copays of $200 to $600 a month or more.2 NPR profiled Jeff La Marca, a 68-year-old in New Jersey with severe sleep apnea and a body mass index of 42. He was denied the Bridge price, and he believes his weight alone would have qualified him if he didn't have the sleep apnea diagnosis.29

The exclusion affects a lot of people. KFF counted about 13.3 million Medicare beneficiaries with obesity or overweight. After removing people with the excluded diagnoses and current GLP-1 users, it estimated that about 3.8 million Part D enrollees qualify for the Bridge.24 By one breakdown of the KFF figures, about 9.7 million enrollees meet the clinical criteria, which means more than half of them are excluded.25 Medical Daily has estimated that roughly 5.9 million enrollees with conditions like diabetes or sleep apnea are left to their regular plans.23 Eli Lilly has described the potential market as about 20 million beneficiaries, far above KFF's count.24 That gap matters: it shows how much the diagnosis rules shrink the program compared with how it is often described.

The $50 sits outside Part D's protections

The second catch is about money. The Bridge runs completely outside the normal Part D benefit. The $50 copay does not count toward the Part D deductible or toward a beneficiary's true out-of-pocket costs, and low-income subsidies don't apply to it.5 TheStreet noted that this means the copay doesn't count toward the $2,100 out-of-pocket cap in 2026, which rises to $2,400 in 2027. It also can't be spread across the year through the Medicare Prescription Payment Plan.4 Coupons and manufacturer discount programs can't be used to lower it either.5

The Extra Help exclusion is the part that matters most for low-income beneficiaries. In 2026, Low-Income Subsidy enrollees pay no more than $5.10 for a generic drug and $12.65 for a brand-name drug, so a $50 monthly bill that never counts toward catastrophic protection is a real new expense for them.4 Aetna's guidance for members confirms that everyone pays the same price, including people who get low-income help.11 The American Action Forum calculated that someone who stays on the drug for all 18 months would pay $900 in copays, none of it counting toward the Part D cap.4

The Bridge price also covers only the drug. Some telehealth companies that handle Bridge prior authorizations charge monthly membership fees of $49 to $299 on top of the copay.3 Those fees are optional, since a patient's own doctor can submit the request. But for people who use these services, the real monthly cost can be several times the advertised $50.

Who pays the rest

The drugmakers sell the drugs to the program at a net price of $245 a month.12 The patient pays $50, so Medicare covers $195 per monthly supply.23 Part D plans carry no financial risk, because a central processor handles prior authorizations, claims and pharmacy payments under a separate billing setup. Pharmacies are reimbursed at the drug's wholesale acquisition cost, minus the copay, plus a dispensing fee.5

That setup is what allowed CMS to move quickly. Medicare has long been barred from covering drugs used only for weight loss, and the Bridge gets around that by sitting outside Part D.14 CMS is running it under its demonstration authority.18 The same workaround explains the diagnosis rules. Because diabetes and sleep apnea treatment already belong to Part D, CMS kept those patients in Part D, even though their copays there are often much higher.

Cost estimates vary widely depending on how many people sign up. Modeling summarized by AJMC estimated Medicare spending of about $1.3 billion to $3.3 billion over 18 months if 10% to 25% of eligible people enroll, and roughly $6.7 billion to $10 billion at 50% to 75% enrollment.24 Modern Healthcare reported that the half-million enrollees equal about 15% of the potential market after two months. That suggests spending could land well above the low end of those estimates.23 CMS has said most authorization requests have been processed in under 12 hours.9 Quick approvals help explain the fast growth, though Walgreens has warned that enrollment could level off.26

The end date is the third catch

The third problem is timing. The Bridge started as a six-month program meant to lead into the BALANCE model, which would have let Part D plans choose to cover GLP-1s for weight loss starting in 2027.15 CMS then postponed BALANCE's Part D portion indefinitely, and a Medicare advocacy group said the reason was too few plans agreeing to take part. CMS extended the Bridge through 2027 at the same time.28 CMS says the extra 18 months of data will go to Part D plan sponsors in case BALANCE is launched later.22

No plan for after December 2027 has been announced. CMS says it will review the data before deciding whether to continue the Bridge.26 KFF's Juliette Cubanski said it is unclear what happens once the 18 months end.4 Walgreens' Rick Gates told Becker's that whether patients have coverage after the program ends is "the biggest watch-out."26 CMS also hasn't said what lookback period it will use in 2027 to identify people who got a GLP-1 through Part D.

Some consumer guides still describe the program with its original 2026 end date or a January 2027 move to BALANCE. Shoppers comparing plans during open enrollment, which runs from October 15 to December 7, should be careful with that outdated information.2025 Medical Daily advises people in the Bridge to make sure any new plan keeps them eligible.23

Where this leaves things

The coverage agrees on the basic facts: the price, the drugs covered, the eligibility tiers, and the fact that the program sits outside Part D. Outlets differ mainly on which catch they treat as most important. NPR emphasized the diagnosis exclusion.2 TheStreet focused on the out-of-pocket cap and Extra Help.4 Pharmacy executives pointed to the end date.26

All three come from the same design choice: keeping weight-loss coverage completely separate from the drug benefit that Congress hasn't changed. That choice made a fast, simple, popular program possible. It also means the price depends on a patient's diagnosis code rather than how sick they are, and the program has no lasting legal basis. The strong demand suggests the separation can't last indefinitely. Either Congress lets Part D cover obesity drugs, an option the Treat and Reduce Obesity Act would provide, or roughly half a million people who have started treatment will face a deadline at the end of 2027.1623